Skip to main content
. 2018 Oct 12;107(5):1587–1597. doi: 10.1002/jbm.b.34251

Table 2.

Antibiotics Concentration in Wound Exudate and Tissue Samples and Information About Possible Influencing Factors

Patient ID Previous Implant Cemented Weight of 24 h Wound Exudate (g) Collected at Spacer Characteristics Antibiotics Concentration in Wound Exudate (μg/mL) Antibiotics Concentration in Tissue Samples (μg/g)
IMP EXP Spacer Cement Mold Usedc Amount (g) of Prepared Cement with [V (g), G (g)] Period of Implantation (Weeks) Vancomycin Gentamicin Vancomycin Gentamicin
IMP EXP IMP EXP IMP EXP IMP EXP
H1a No 186 Palacos R+G M1 160 [8.0, 2.0] 12.6 17.46 n.c. 20.80 n.c. 0.00* 0.09
H1 2nd spacer n.c. Palacos R+G n.s. 40 [2.0, 0.5] 10.0 0.04 0.16
H2b Yes 133 182 Palacos R+G M3 160 [8.0, 2.0] 11.1 27.06 17.67 6.69 12.53 0.01 39.49 0.15 1.07
H3 No 302 123 Palacos R+G M3 160 [8.0, 2.0] 11.7 10.37 11.37 3.67 9.44 0.00* 0.26 0.01* 0.13
H4b Yes 263 172 Palacos R+G M3 160 [8.0, 2.0] 12.4 92.73 5.47 71.80 0.74 0.00* 0.38 25.81 0.05
H5a No n.c. n.c. Palacos R+G M3 160 [8.0, 2.0] 11.6 n.c. n.c. n.c. n.c. 0.00* 484.16 0.01* 71.75
H6 No 167 Palacos R+G M3 80 [4.0, 1.0] 2.6 43.28 21.55 0.00* 0.01*
H6 2nd spacer 571 Palacos R+G n.s. 60 [3.0, 0.75] 15.0 0.13* 53.87 0.02 0.05
H7 No 213 98 Palacos R+G M1 80 [4.0, 1.0] 11.1 50.25 37.47 23.01 12.77 0.00* 0.12 0.01* 0.12
H8b No 552 Palacos R+G n.s. 40 [2.0, 0.5] 2.1 63.24 19.49 9.36 0.01*
H8 2nd spacer 12 Palacos R+G M3 160 [8.0, 2.0] 12.3 0.44 0.01 0.23 0.70
H9 No 478 31 Palacos R+G M3 140 [7.0, 1.75] 12.7 189.05 0.82 15.63 10.32 0.00* 16.31 0.01* 17.98
H10 No 359 357 Palacos R+G M3 160 [8.0, 2.0] 11.4 27.82 0.33 9.38 17.25 0.01 0.29 0.01* 0.87
K1a Yes 425 n.c. Palacos R+G T4+F4 160 [8.0, 2.0] 16.0 50.19 n.c. 18.73 n.c. 0.26 0.99 42.93 0.91
K2a Yes 384 n.c. Copal spacem T4+F4 160 [8.0, 2.0] 11.6 56.18 n.c. 7.06 n.c. 0.00* 26.20 1.50 3.92
K3 Yes 151 Palacos R+G T3+F3 120 [6.0, 1.5] 2.0 0.28 52.54 0.01 18.83
K3 2nd spacer 399 Palacos R+G T4+F4 180 [2.25, 9.0] 18.4 0.62 104.02 0.37 3.84
K4 Yes 174 367 Copal spacem T2+F2 120 [6.0, 1.5] 9.3 93.58 0.13* 5.82 9.14 0.00* 0.03 1.35 0.01*
K5 No 324 180 Palacos R+G T3+F3 120 [6.0, 1.5] 9.3 261.22 0.37 15.28 17.53 0.00* 0.07 0.01* 0.05
K6 Yes 447 93 Palacos R+G T4+F4 160 [8.0, 2.0] 12.1 27.61 30.32 12.71 11.64 0.00* 0.99 31.83 6.24
K7 Yes 193 542 Copal spacem T4+F4 160 [8.0, 2.0] 13.9 33.51 0.13* 14.74 59.17 0.00* 0.32 1.70 0.41
K8 Yes 177 5 Palacos R+G T3+F3 160 [8.0, 2.0] 14.9 143.09 0.46 84.60 8.40 0.00* 15.03 8.45 19.13

All values excluded from the statistical analysis and from depiction in Figures 1 and 2 are underlaid in gray.

Abbreviations: H = hip patient; K = knee patient; IMP = spacer implantation; EXP = spacer explantation; V = vancomycin; G = gentamicin; n.c. = not collected.

a

Patient excluded from analysis of wound exudate due to missing sample at spacer explantation.

b

Patient excluded from analysis of vancomycin release due to systemic antibiotics therapy with vancomycin at time point of sample collection.

c

Spacer molds hip with stem size/head size: spacer mold 1 (M1) with 9 × 125 mm/43 mm; spacer mold 2 (M2) 9 × 125 mm/51 mm; spacer mold 3 (M3) 13 × 145 mm/57 mm; spacer mold 4 (M4) 17 × 165 mm/64 mm. Spacer molds knee with tibia and femur: spacer mold tibia 1 (T1) 65 mm M/Lx 39 mm A/P; spacer mold tibia 2 (T2) 70 mm M/Lx 42 mm A/P; spacer mold tibia 3 (T3) 75 mm M/Lx 45 mm A/P; spacer mold tibia 4 (T4) 80 mm M/Lx 48 mm A/P; spacer mold femur 1 (F1) 60 mm M/Lx 43 mm A/P; spacer mold femur 2 (F2) 65 mm M/Lx 48 mm A/P; spacer mold femur 3 (F3) 70 mm M/Lx 52 mm A/P; spacer mold femur 4 (F4) 75 mm M/Lx 57 mm A/P.

*

Values below the detection limit. Lower limit of quantification (LLOQ) for gentamicin were 0.008 μg/g in periprosthetic membrane samples and 0.004 μg/mL in wound exudates, LLOQs for vancomycin were 0.0025 μg/g in periprosthetic membrane samples and 0.125 μg/mL in wound exudates. Values below the detection limit were set at the value of the LLOQ for depiction and statistical analysis.